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Ospedaliera Universitaria Policlinico di Palermo:  S. Siragusa, MD (13); Trieste, Italy- Medicina di 
Urgenza, Ospedale Cattinara: R. Salvi, MD; M. Miccio, MD (12); Gallipoli, Italy – Medicina 
Interna e Lungodegenza, Ospedale Sacro Cuore di Gesù: L. Ria, MD (12); Vittorio Veneto, Treviso, 
Italy - Ospedale Civile,: N. Zanatta, MD (12); Florence, Italy – Thrombosis Centre, Department of 
Heart and Vessels Azienda Ospedaliero-Universitaria Careggi: D. Poli, MD (11); Padua, Italy – 
Unit of Angiology, University Hospital of Padua: G. Camporese, MD; F. Verlato, MD (11); 
Ancona, Italy – Medicina di Urgenza, Ospedali Riuniti Umberto I - Lancisi- Salesi: A. Salvi, MD; 
C. Nitti, MD (11); Alessandria, Italy - Ospedale Civile S Antonio, Biagio e Arrigo: R. Santi, MD 
(10); Vimercate, Italy - Department of Medicine, Vimercate Hospital, Azienda Ospedaliera di Desio 
e Vimercate (Monza-Brianza): C. Cimminiello, MD (8); Treviso, Italy - Ospedale Ca’ Foncello,: G. 
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Pasca, MD (8); Domodossola, Italy: Ospedale S Biagio: E. De Gaudenzi, MD (7); Siena, Italy: 
Università di Siena: R. Cappelli, MD (6); Naples, Italy – Regional Reference Centre for 
Coagulation Disorders, Department of Clinical and Experimental Medicine, Federico II University 
Hospital: G. Di Minno, MD; A. Tufano, MD (6); Fano, Italy – Ospedale di Fano: G. Frausini, MD 
(6); Cosenza, Italy - Department of Internal Medicine, Azienda ospedaliera: C. Bova, MD (5); 
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Monza, Italy - Università Milano Bicocca: E. Pogliani, MD (4); Catania, Italy – Angiologia, 
Ospedale Garibaldi: S.S. Signorelli, MD (4); Cremona, Italy – Haemostasis and Thrombosis Centre, 
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Universitaria Careggi: S. Grifoni, MD (2); Milan, Italy - Thrombosis Center, IRCCS Istituto Clinico 
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APPENDIX  
 
Exclusion criteria 
The main exclusion criteria were known cancer; known major thrombophilia 
(antiphospholipid antibodies or lupus anticoagulant or homozygous factor V Leiden or prothrombin 
G21210A or double heterozygosity for factor V Leiden and prothrombin G21210A or deficiency of 
antithrombin, protein C or S); an indication for long-term anticoagulant therapy other than venous 
thromboembolism (as atrial fibrillation or prosthetic heart valve); previous symptomatic 
complications of atherosclerosis requiring treatment with aspirin or other anti-platelet agents; active 
bleeding or high risk for bleeding or a bleeding episode which occurred during the 6-18 months of 
anticoagulation; known allergy or intolerance to aspirin; life expectancy shorter than six months; 
anticipated non-adherence to study medications; pregnancy or breast-feeding; participation in 
another experimental pharmacotherapeutic program within 30 days before randomization. Women 
with venous thromboembolism associated with the use of estro-progestin therapy were excluded 
from the study. 
Criteria for diagnosis of recurrent venous thromboembolism 
The criteria for the diagnosis of recurrence of pulmonary embolism were a new intraluminal 
filling defect on computed tomography angiography or pulmonary angiography, or a new high 
probability perfusion defect on lung scan. In limbs without deep vein thrombosis at baseline, the 
criteria for the diagnosis of recurrence of deep vein thrombosis was a non-compressible venous 
segment on ultrasonography or an intraluminal filling defect on venography. In limbs with deep 
vein thrombosis at baseline, the criteria for the diagnosis of recurrence of deep vein thrombosis 
were a newly non-compressible venous segment or a substantial increase (4 millimeters or more) in 
the diameter of the thrombus during full compression on ultrasonography or a new intraluminal 
filling defect on venography. 
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Surveillance and follow-up 
At each visit, patients were systematically questioned concerning symptoms and signs of 
recurrent venous thromboembolism, bleeding, and adverse events.  
Other anticoagulants and fibrinolytic agents were not allowed during the study period. The 
administration of non-steroidal anti-inflammatory drugs was allowed with caution if considered 
necessary.  
 
